Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (611)	8/20/2001 8:31:14 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 2243

No special details. Asked for ASCO poster reprint, but never got answer. From PR: <<Serum levels of BAY 43-9006 observed in preclinical models, which demonstrated antitumor activity, have been achieved in the Phase I dose escalating clinical trial, but dose escalation in this study continues since the companies believe a maximum tolerated dose has not yet been reached. >. And from ASCO abstract: <<To date, PK data resulted in Cmax values in a range of 0.74 to 3.6 mg/L after 2.0 to 14 h and an AUC range of 19 to 110 mgh/L at doses from 50 to 400 mg (geom. mean of 3 pts. each). A terminal half life of 35 h (geom. mean) was observed. Administration with or without breakfast did not lead to an observed difference in absorption. Splitting of doses (2100 and 3*100 mg) increased exposure favorably. The dosing regimen will be modified to achieve the target AUC associated with antineoplastic efficacy in preclinical models. Patient accrual continues to define the MTD.>> Slow absorption and pure bioaveability (pure solubility) may be a big problem for cancer drug, gut toxicity. Also, Bayer reputation in cancer field is high failure rate. I do not believe that ONXX-Bayer chemists can solve problems for difficult target as Raf is. Miljenko